

Ludovic Lacroix

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8394810/publications.pdf>

Version: 2024-02-01

27
papers

1,421
citations

623734

14
h-index

552781

26
g-index

28
all docs

28
docs citations

28
times ranked

3288
citing authors

#	ARTICLE	IF	CITATIONS
1	The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies. <i>Cancer Discovery</i> , 2022, 12, 1266-1281.	9.4	67
2	Clinical utility and outcomes impact of crystal digital PCR of sensitizing and resistance EGFR mutations in patients with advanced non-small cell lung cancer. <i>Clinical Lung Cancer</i> , 2022, , .	2.6	0
3	Genomic landscape of acquired resistance to targeted therapies in patients with solid tumors: A study from the National Center for Precision Medicine (PRISM).. <i>Journal of Clinical Oncology</i> , 2022, 40, 3016-3016.	1.6	1
4	Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test. <i>Cells</i> , 2022, 11, 1901.	4.1	9
5	Comprehensive Genome Profiling in Patients With Metastatic Nonâ€“Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 4018-4026.	7.0	4
6	Minimal residual disease (MRD) in patients with resected stage I NSCLC: Results of the prospective adjuvant IFCT-0703 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8526-8526.	1.6	1
7	Maintenance targeted therapy compared to standard of care (SoC) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): Results from the phase II randomized UNICANCER/IFCT1301-SAFIR02-LUNG intergroup trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9095-9095.	1.6	0
8	Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large <sc>B</sc>â€“cell lymphoma: Results of <sc>LNHâ€“EP1</sc> study. <i>American Journal of Hematology</i> , 2021, 96, E376-E379.	4.1	2
9	Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with <i>BRAF</i>-Mutant Metastatic Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6242-6253.	7.0	23
10	DNA FISH Diagnostic Assay on Cytological Samples of Thyroid Follicular Neoplasms. <i>Cancers</i> , 2020, 12, 2529.	3.7	3
11	Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 3758.	3.7	4
12	Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E nonâ€“small cell lung cancer. <i>European Journal of Cancer</i> , 2020, 132, 211-223.	2.8	53
13	High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1232-1239.	1.1	29
14	Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in <i>ALK</i>-Rearranged Nonâ€“Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6671-6682.	7.0	95
15	Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. <i>European Journal of Cancer</i> , 2018, 92, 1-10.	2.8	14
16	Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenaseâ€“mutated intrahepatic cholangiocarcinomas. <i>European Journal of Cancer</i> , 2018, 90, 83-91.	2.8	28
17	Does smoking alter the mutation profile of human papillomavirusâ€“driven head and neck cancers?. <i>European Journal of Cancer</i> , 2018, 94, 61-69.	2.8	29
18	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. <i>Oncotarget</i> , 2018, 9, 9741-9750.	1.8	12

#	ARTICLE	IF	CITATIONS
19	First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma. <i>Anticancer Research</i> , 2018, 38, 2909-2914.	1.1	3
20	Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. <i>Clinical Cancer Research</i> , 2017, 23, 6101-6112.	7.0	102
21	LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. <i>Lung Cancer</i> , 2017, 112, 62-68.	2.0	92
22	Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. <i>European Journal of Cancer</i> , 2017, 87, 122-130.	2.8	120
23	Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. <i>PLoS Medicine</i> , 2016, 13, e1002201.	8.4	300
24	Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations. <i>Cancer Research</i> , 2016, 76, 5954-5961.	0.9	16
25	Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. <i>BMC Cancer</i> , 2015, 15, 26.	2.6	49
26	Genomes in the clinic: the Gustave Roussy Cancer Center experience. <i>Current Opinion in Genetics and Development</i> , 2014, 24, 99-106.	3.3	10
27	Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIRO1/UNICANCER). <i>Lancet Oncology</i> , The, 2014, 15, 267-274.	10.7	351